title: Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
authors.forename: Emilio
authors.initials: E
authors.lastname: Bria
authors.forename: Paolo
authors.initials: P
authors.lastname: Carlini
authors.forename: Francesco
authors.initials: F
authors.lastname: Cognetti
authors.forename: Edmondo
authors.initials: E
authors.lastname: Terzoli
authors.forename: Diana
authors.initials: D
authors.lastname: Giannarelli
mesh_terms: D000730:Androstadienes / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D015201:Meta-Analysis as Topic; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000401:mortality; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012107:Research Design; D016019:Survival Analysis
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; C056516:exemestane